Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for lymphomas.

John M Timmerman1

  • 1Division of Hematology/Oncology, University of California, Center for Health Sciences, Los Angeles, California 90095-1678, USA. jtimmerman@mednet.ucla.edu

International Journal of Hematology
|July 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal of hematology & oncology·2026
Same author

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Blood advances·2025
Same author

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma.

Blood advances·2025
Same author

Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.

Transplantation and cellular therapy·2024
Same author

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.

Bone marrow transplantation·2024
Same author

Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023
Same journal

Cytarabine-based induction and oral maintenance therapy for a single system with single-site Langerhans cell histiocytosis.

International journal of hematology·2026
Same journal

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

International journal of hematology·2026
Same journal

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

International journal of hematology·2026
Same journal

The efficacy of prophylactic tranexamic acid in patients with hematologic malignancy: a systematic review and meta-analysis.

International journal of hematology·2026
Same journal

Current status and challenges of TCR-T cell therapy for AML/MDS.

International journal of hematology·2026
Same journal

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study.

International journal of hematology·2026
See all related articles

Immunotherapy offers new hope for B-cell lymphomas, a highly immune-responsive cancer. While cytokine therapies failed, monoclonal antibodies like rituximab and emerging vaccines show promise for treating lymphoid malignancies.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • B-cell lymphomas, especially follicular lymphoma, are highly responsive to immune system intervention.
  • Previous systemic cytokine therapies have yielded disappointing results for B-cell malignancies.

Purpose of the Study:

  • To review current and emerging immunotherapeutic strategies for lymphoid malignancies.
  • To highlight the impact of monoclonal antibodies and therapeutic vaccines in B-cell lymphoma treatment.

Main Methods:

  • Review of existing literature on immunotherapy for B-cell lymphomas.
  • Analysis of clinical trial data for monoclonal antibodies (e.g., anti-CD20) and various vaccine platforms.

Main Results:

  • Anti-CD20 monoclonal antibody therapy (rituximab) has significantly impacted treatment protocols for B-cell lymphomas.

Related Experiment Videos

  • Therapeutic vaccines targeting idiotype are showing promise in early-phase trials and advancing to phase III.
  • Diverse vaccine strategies including dendritic cell, protein, DNA, heat shock protein, and gene-modified cell vaccines are under development.

    • Conclusions:

    • Immunotherapy, particularly monoclonal antibodies and vaccines, represents a significant advancement in treating B-cell lymphomas.
    • Combination immunotherapy approaches hold potential for effective treatment, possibly reducing reliance on conventional chemotherapy.
    • Further research and clinical trials are crucial to optimize immunotherapeutic strategies for lymphoid malignancies.